These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

189 related items for PubMed ID: 29498910

  • 1. ACUTE PHASE REACTIONS AFTER ZOLEDRONIC ACID INFUSION: PROTECTIVE ROLE OF 25-HYDROXYVITAMIN D AND PREVIOUS ORAL BISPHOSPHONATE THERAPY.
    Crotti C, Watts NB, De Santis M, Ceribelli A, Fabbriciani G, Cavaciocchi F, Marasini B, Selmi C, Massarotti M.
    Endocr Pract; 2018 May; 24(5):405-410. PubMed ID: 29498910
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Serum 25-hydroxyvitamin D levels modulate the acute-phase response associated with the first nitrogen-containing bisphosphonate infusion.
    Bertoldo F, Pancheri S, Zenari S, Boldini S, Giovanazzi B, Zanatta M, Valenti MT, Dalle Carbonare L, Lo Cascio V.
    J Bone Miner Res; 2010 Mar; 25(3):447-54. PubMed ID: 20200999
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Multicenter Study on Observation of Acute-phase Responses After Infusion of Zoledronic Acid 5 mg in Chinese Women with Postmenopausal Osteoporosis.
    Ding Y, Zeng JC, Yin F, Zhang CL, Zhang Y, Li SX, Liu X, Zhang C, Xue QY, Lin H, Pei FX.
    Orthop Surg; 2017 Aug; 9(3):284-289. PubMed ID: 28960821
    [Abstract] [Full Text] [Related]

  • 6. Intravenous bisphosphonates for postmenopausal osteoporosis: safety profiles of zoledronic acid and ibandronate in clinical practice.
    Sieber P, Lardelli P, Kraenzlin CA, Kraenzlin ME, Meier C.
    Clin Drug Investig; 2013 Feb; 33(2):117-22. PubMed ID: 23184667
    [Abstract] [Full Text] [Related]

  • 7. Characterization of and risk factors for the acute-phase response after zoledronic acid.
    Reid IR, Gamble GD, Mesenbrink P, Lakatos P, Black DM.
    J Clin Endocrinol Metab; 2010 Sep; 95(9):4380-7. PubMed ID: 20554708
    [Abstract] [Full Text] [Related]

  • 8. Acute phase response following intravenous zoledronate in postmenopausal women with low bone mass.
    Anastasilakis AD, Polyzos SA, Makras P, Sakellariou GT, Bisbinas I, Gkiomisi A, Delaroudis S, Gerou S, Ballaouri I, Oikonomou D, Papapoulos SE.
    Bone; 2012 May; 50(5):1130-4. PubMed ID: 22366634
    [Abstract] [Full Text] [Related]

  • 9. Gamma-delta T lymphocytes and 25-hydroxy vitamin D levels as key factors in autoimmunity and inflammation: the case of zoledronic acid-induced acute phase reaction.
    De Santis M, Cavaciocchi F, Ceribelli A, Crotti C, Generali E, Fabbriciani G, Selmi C, Massarotti M.
    Lupus; 2015 Apr; 24(4-5):442-7. PubMed ID: 25801887
    [Abstract] [Full Text] [Related]

  • 10. Effect of acetaminophen and fluvastatin on post-dose symptoms following infusion of zoledronic acid.
    Silverman SL, Kriegman A, Goncalves J, Kianifard F, Carlson T, Leary E.
    Osteoporos Int; 2011 Aug; 22(8):2337-45. PubMed ID: 21116816
    [Abstract] [Full Text] [Related]

  • 11. Addition of dexamethasone to manage acute phase responses following initial zoledronic acid infusion.
    Chen FP, Fu TS, Lin YC, Lin YJ.
    Osteoporos Int; 2021 Apr; 32(4):663-670. PubMed ID: 33113007
    [Abstract] [Full Text] [Related]

  • 12. Effect of single-dose dexamethasone on acute phase response following zoledronic acid: a randomized controlled trial.
    Billington EO, Horne A, Gamble GD, Maslowski K, House M, Reid IR.
    Osteoporos Int; 2017 Jun; 28(6):1867-1874. PubMed ID: 28233020
    [Abstract] [Full Text] [Related]

  • 13. The Interaction of Acute-Phase Reaction and Efficacy for Osteoporosis After Zoledronic Acid: HORIZON Pivotal Fracture Trial.
    Black DM, Reid IR, Napoli N, Ewing SK, Shiraki M, Nakamura T, Takeuchi Y, Schafer AL, Kim TY, Cauley JA.
    J Bone Miner Res; 2022 Jan; 37(1):21-28. PubMed ID: 34585443
    [Abstract] [Full Text] [Related]

  • 14. No effect of rosuvastatin in the zoledronate-induced acute-phase response.
    Makras P, Anastasilakis AD, Polyzos SA, Bisbinas I, Sakellariou GT, Papapoulos SE.
    Calcif Tissue Int; 2011 May; 88(5):402-8. PubMed ID: 21305270
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Circulating γδ T cells and the risk of acute-phase response after zoledronic acid administration.
    Rossini M, Adami S, Viapiana O, Ortolani R, Vella A, Fracassi E, Gatti D.
    J Bone Miner Res; 2012 Jan; 27(1):227-30. PubMed ID: 21956654
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.